FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy

Full Text:


Aim. The study aimed to evaluate the pharmacoeconomic feasibility of propranolol application in the dosage form of the oral solution in the treatment of proliferating infantile hemangioma requiring systemic therapy.

Materials and methods. The study design was a retrospective analysis of the published data. The methods of pharmacoeconomic analysis included a clinical-economic analysis (cost-effectiveness analysis) with a sensitivity analysis; and a "budget impact" analysis with a sensitivity analysis. The authors compared the pharmacoeconomic effectiveness of pharmacotherapy for infant hemangiomas with propranolol and surgical methods of treatment.

Results. The efficacy of propranolol therapy was 39% higher than surgical methods of treatment. The relative increase in the efficacy of propranolol therapy compared to surgical treatments was 68.4%. At the same time, the cost of propranolol therapy was lower than the cost of surgical treatments by 31.7% or 56,486,07 RUR per patient per year. The application of propranolol in the treatment for proliferating infantile hemangioma allowed reducing the burden on the budget of the state guarantee program in comparison with surgical methods of treatment for 3 years by 1,562.0 million RUR with a proportion of 12% of patients with infant hemangiomas requiring systemic therapy (9,694 patients per year). The sensitivity analysis of the cost and effectiveness of the compared medical technologies showed that the obtained results are resistant to the fluctuations in these parameters in the range from − 20% to + 20%.

Conclusion. The application of propranolol preparation in a dosage form of oral solution for the treatment of patients with proliferating infantile hemangioma will significantly increase the efficiency of therapy and reduce costs associated with the application of surgical methods of treatment.

About the Authors

I. N. Dyakov
Scientific and Practical Center for the Study of the Problems of Rational Pharmacotherapy and Pharmacoeconomics; Research Institute of Vaccines and Serums named after I.I. Mechnikov
Russian Federation

Ilya N. Dyakov - MD, PhD in Biology, General Director, Scientific and Practical Center for the Study of the Problems of Rational Pharmacotherapy and Pharmacoeconomics; Head of the Laboratory of Immunoglobulin Biosynthesis; Leading Researcher, RIVS named after I.I. Mechnikov, Scopus Author ID: 25723245000; WOS Reseacher ID: K-2024-2018; RSCI SPIN-code: 1854-0958; eLIBRARY ID: 180423.

50, bld. 2 Aviamotornaya Str., Moscow 111024; 5A Malyy Kazennyy pereulok, Moscow 105044

S. R. Varfolomeеva
Federal State Budgetary Institution N.N. Blokhin National MedicaI Research Center or Oncology» or the Ministry of the Health of the Russian Federation
Russian Federation

Svetlana R. Varfolomeeva - MD, Dr Sci Med, Professor, Deputy Director for Scientific and Clinical Work - Director of the Scientific Research Institute of Pediatric Oncology and Hematology of the Administrative Department, N.N. Blokhin NMRCO.

Kashirskoe shosse, 23, Moscow 115478


1. Hoeger P.H., Harper J.I., Baselga E., Bonnet D., Boon L.M., Ciofi Degli Atti M., El Hachem M., Oranje A.P., Rubin A.T., Weibel L., LéautéLabrèze C. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015 Jul; 174 (7): 855–65.

2. Dickison P., Christou E., Wargon O. A prospective study of infantile hemangiomas with a focus on incidence and risk factors. Pediatr Dermatol. 2011; 28: 663–669.

3. Luu M., Frieden I.J. Haemangioma: clinical course, complications and management. Brit J Dermatol. 2013; 169: 20–30.

4. Metry D., Frieden I.J., Hess C., Siegel D., Maheshwari M., Baselga E., Chamlin S., Garzon M., Mancini A.J., Powell J., Drolet B.A. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol. 2013; 30: 71–89.

5. Munden A., Butschek R., Tom W.L., Marshall J.S., Poeltler D.M., Krohne S.E., Alió A.B., Ritter M., Friedlander D.F., Catanzarite V., Mendoza A., Smith L., Friedlander M., Friedlander S.F. Prospective study of infantile hemangiomas: incidence, clinical characteristics and association with placental anomalies. 2014; Brit J Dermatol. 170: 907–913.

6. Krowchuk D.P., Frieden I.J., Mancini A.J., Darrow D. H., Blei F., Greene A.K., Annam A., Baker C. N., Frommelt P.C., Hodak A., Pate B. M., Pelletier J. L., Sandrock D., Weinberg S. T., Whelan M. A. Subcommittee on the management of infantile hemangiomas. Pediatrics. Jan 2019; 143 (1): e20183475.

7. Drolet B. A. Dose selection and use of propranolol for the treatment of infantile hemangioma: report of the consensus conference-Pediatrics. 2012.

8. Filippi L., Cavallaro G., Bagnoli P., DalMonte M., Fiorini P., Donzelli G., Tinelli F., Araimo G., Cristofori G., la Marca G., Della Bona M.L., La Torre A., Fortunato P., Furlanetto S., Osnaghi S., Mosca F. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013; 163: 1570–1577.

9. Haggstrom A.N., Drolet B.A., Baselga E., Chamlin S.L., Garzon M.C., Horii K.A., Lucky A.W., Mancini A.J., Metry D.W., Newell B., Nopper A.J., Frieden I.J. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007; 150: 291–294.

10. Drolet B.A., Swanson E.A., Frieden I.J. Hemangioma Investigator Group. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr. 2008; 153: 712–5.

11. Draft clinical guidelines “Infant hemangioma”, developed by the Russian Association of Pediatric Surgeons in 2020 (in Russ). [Electronic resource] URL: Accessed: 12.10.2020.

12. Clinical protocol for medical care for vascular formations and malformations of the face and neck. Association of Oral and Maxillofacial Surgeons and Dental Surgeons. 2014; 24 с. (in Russ)

13. Decree of the Government of the Russian Federation of 08/28/2014 N 871 (as amended on 11/20/2018) “On approval of the Rules for the formation of lists of drugs for medical use and the minimum range of drugs necessary for the provision of medical care” (in Russ).

14. Instructions for medical use of the medicinal product propranolol in the dosage form of a solution for oral administration (Gemangiol®) (in Russ) [Electronic resource] URL: Accessed: 12.10.2020

15. Methodical recommendations for the comparative clinical and economic assessment of the medicinal product. Center for Healthcare Quality Assessment. 2018; 48 с. (in Russ)

16. Guidelines for assessing the impact on the budget in the framework of the implementation of the Program of state guarantees of free medical care to citizens. Center for Healthcare Quality Assessment. 2018; 40 с. (in Russ)

17. Instructions on grouping cases, including the rules for accounting for classification criteria, and approaches to payment for medical care in an outpatient setting. Joint letter dated 12.12.2019 from the Ministry of Health of the Russian Federation No. 11-7 / I / 2-11779 and the Federal Compulsory Medical Insurance Fund No. 17033 / 26-2 № 17033/26-2/и (in Russ). [Electronic resource] URL: Accessed: 25.09.2020

18. “On the Program of state guarantees of free provision of medical care to citizens for 2020 and for the planning period of 2021 and 2022”. Resolution of December 7, 2019 No. 1610. Government of the Russian Federation. Moscow (in Russ).

19. Liu X., Qu X., Zheng J., Zhang L. Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis. PLoS One. 2015 Sep 16; 10 (9): e0138100.

20. World Health Organization. Growth rates of children. Body weight – age (in Russ). [Electronic resource] URL:

21. Official site of the Federal State Statistics Service. Home / Statistics / Official statistics / Population / Demographics (in Russ). [Electronic resource] URL: Accessed: 26.10.2020.


For citations:

Dyakov I.N., Varfolomeеva S.R. Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):356-365. (In Russ.)

Views: 532

ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)